With TECH, you will be up to date on the major advances in modern Psychopharmacology, with an educational modality that combines in an exceptional way the practical and theoretical knowledge of this area of health"

Psychopharmacology has incorporated different medical contributions in recent years. From it, the health sector has been able to outline more personalized intervention strategies according to the symptomatology of each patient. At the same time, this discipline has investigated the discovery of neurotransmitters that condition a more efficient response to specific substances in pathologies such as Schizophrenia or Bipolar Disorder. This branch of science has also searched for those genes related to a certain psychological or psychiatric phenomenon in order to investigate the drug with the greatest precession against them. Simultaneously, the mastery of all these advances is a challenge for specialists in a context where the programs in this respect have a high theoretical load.

TECH, in its eagerness to contribute to the training of excellence of specialists, has designed a Hybrid Master's Degree that overcomes these shortcomings. To this end, it has developed an educational modality, pioneer in its kind, where knowledge and skills will be addressed in two different ways. First, the graduate will be updated on the latest trends in Psychopharmacology in a theoretical way. The contents in this pedagogical phase will be arranged in a 100% online and interactive learning platform. From there, you will access a syllabus prepared by distinguished experts and, under their personalized guidance, assimilate concepts quickly and flexibly.

Then, in a practical and face-to-face internship that lasts 3 weeks, the professional will develop different skills related to the mastery of the previous phase. In an intensive and immersive way, he will analyze the drugs, or combinations of them, that best fit real patients under his responsibility. He will also be mentored by an assistant tutor who will closely monitor his progress. The clinical training will take place in a hospital institution of maximum rigor, which will be chosen by the student, according to his immediate geographical location.

The use of drugs at the end of life, as part of the palliative care against pain, is another of the innovative edges that you will analyze through this Hybrid Master's Degree"

This Hybrid Master's Degree in Psychopharmacology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Development of more than 100 clinical cases presented by Psychopharmacology professionals
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Comprehensive systematized action plans for the main pathologies
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• Practical clinical guides on approaching different pathologies
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection
• Furthermore, you will be able to carry out a clinical internship in one of the best medical centers

Don't hesitate any longer and enroll in this program that provides you with 1,620 hours of the best theoretical and practical learning about the most modern medications to stop Depression and convulsive behaviors"

In this Professional Master's Degree proposal, of a professionalizing nature and hybrid learning modality, the program is aimed at updating Psychopharmacology professionals who require a high level of qualification. The contents are based on the latest scientific evidence, and are oriented in a didactic way to integrate theoretical knowledge into medical practice, and the theoretical-practical elements will facilitate the updating of knowledge and will allow decision making in patient management.

Thanks to its multimedia content elaborated with the latest educational technology, it will allow health care professional to obtain a situated and contextual learning, that is to say, a simulated environment that will provide an immersive learning programmed to train in real situations. This program is designed around Problem-Based Learning, whereby the physician must try to solve the different professional practice situations that arise during the course. For this purpose students will be assisted by an innovative interactive video system developed by renowned experts.

During the practical phase of this program, you will develop new skills for the pharmacological management of patients with eating and sleep disorders"

This Hybrid Master's Degree has been designed for you to be part of the medical forefront, with a complete vision of the advantages and contributions of Psychopharmacology"

This syllabus, designed by the best experts, delves into the latest advances in pharmacology to respond to psychological and psychiatric problems that patients may face. Throughout this theoretical phase, the physician will explore the most advanced criteria of intervention through medications for Stress, Anxiety, Obsessive Convulsive Disorders, psychotic episodes, among others. At the same time, he will delve into the best combination strategies of these pharmaceutical products and which are their most frequent contraindications. To complete the assimilation of these contents, the specialist will have at his disposal innovative didactic methods such as Relearning.

Using multimedia resources and interactive summaries, you will assimilate the modules of this program in a fast and flexible way"

Module 1. Pharmacology and Its Objectives in the Psychological Therapeutic Process

1.1. Anthropological, Historical, Sociological and Psychological Perspective of the Use of Drugs
1.2. Objectives of Pharmacology
1.3. Concept of Pharmacology
1.4. Therapeutic Pharmacology
1.5. Pharmacodynamics
1.6. Pharmacokinetics
1.7. Plasma Level Curve
1.8. Toxicology
1.9. Social Aspects of the Drug
1.10. Medication Intervention Process
1.11. Information form for the Patient Who Is Going to Receive Psychopharmacological Treatment
1.12. Process for a Drug to Become Legal
1.13. Signs and Symptoms. Diseases and Syndromes

Module 2. Anamnesis and the Decision to Choose the Appropriate Drug

2.1. Active Interview (CHSV)
2.2. Information Theory
2.3. Communication Channels
2.4. Communication System
2.5. Axioms of the Interview
2.6. It is Impossible Not To Communicate
2.7. Content and Relationship
2.8. Affective Value
2.9. Digital and Analog Communication
2.10. Symmetric and Asymmetric
2.11. Exploring Communication
2.12. Verbal Communication
2.13. Non-Verbal Communication
2.14. Double Bond
2.15. Psychopathology of Communication
2.16. A Gesture is Worth a Thousand Words
2.17. Medical History
2.18. General Structure of the Mental Examination
2.19. Semiology
2.20. Epistemology of Diagnosis
2.21. Some Special Types of Clinical Interviews

Module 3. Classification of Psychotropic Drugs

3.1. Neurophysiological Bases of Mental Illness and Its Treatment
3.2. Antipsychotics and Neuroleptics
3.3. Anxiolytics and Sedatives
3.4. Antidepressants
3.5. Antimanic or Euthymic Drugs
3.6. Antiseizure Medications
3.7. Medications for Agitation
3.8. Pharmacotherapy of Confusion
3.9. Drugs for Dementia
3.10. Medication Against Deficiencies

Module 4. Pharmacological Intervention in Anxiety and Stress Disorders

4.1. Anxiety or Panic Disorder
4.2. Agoraphobia
4.3. Social Phobia
4.4. Specific Phobias
4.5. Generalized Anxiety Disorder
4.6. Obsessive Compulsive Disorder and Related Disorders
4.7. Separation Anxiety Disorder
4.8. Adaptive Disorder
4.9. Dissociative Disorders
4.10. Somatic Symptom Disorders and Associated Conditions
4.11. Trauma and Stress-Related Disorders
4.12. Post-Traumatic Stress
4.13. Disinhibited Social Relationship Disorder

Module 5. Intervention with Psychotropic Drugs in Depression, Eating Disorders, and Sleep Disorders

5.1. Disruptive Mood Dysregulation Disorder
5.2. Major Depressive Disorder
5.3. Persistent Depressive Disorder (Dysthymia)
5.4. Premenstrual Dysphoric Disorder
5.5. Substance-Induced Depressive Disorder
5.6. Pica
5.7. Rumination Disorder
5.8. Food Avoidance Disorder
5.9. Anorexia Nervosa
5.10. Bulimia Nervosa
5.11. Binge Eating Disorder
5.12. Insomnia
5.13. Hypersomnia
5.14. Narcolepsy
5.15. Obstructive Sleep Apnea
5.16. Sleep-Related Hypoventilation
5.17. Non-REM Sleep Awakening Disorders
5.18. Nightmare Disorder
5.19. Restless Leg Syndrome

Module 6. Pharmacotherapy of Psychosis and Dementias

6.1. Schizophrenia and Schizophreniform Psychoses
6.2. Delusional Disorder
6.3. Brief Psychotic Disorder
6.4. SubstanceInduced Psychotic Disorder
6.5. Catatonia
6.6. Bipolar Disorder
6.7. Cyclothymic Disorder
6.8. Delirium
6.9. Alzheimers Disease
6.10. Frontotemporal Lobe Degeneration
6.11. Dementia due to Brain Trauma
6.12. Vascular Dementia
6.13. Dementia Due to Parkinson's Disease
6.14. Dementia due to Huntington's Disease
6.15. Personality Disorders
6.16. Latrogenia

Module 7. Drugs Used in the Pain Unit

7.1. Clinical History of the Pain Patient
7.2. Psychosocial Approach Chronic Pain
7.3. Patient-Controlled Analgesia (PCA)
7.4. Pain in Polytraumatic Patients
7.5. Pain in Severe Burns
7.6. Headaches and Facial Pain
7.7. Treatment of Neuralgia
7.8. Treatment of Oncologic Pain
7.9. Pain and Terminal Sedation
7.10. Fibromyalgia

Master the latest theoretical trends in Psychopharmacology using innovative didactic methods such as Relearning"